CSBio CSBio

X
[{"orgOrder":0,"company":"PharmaMar","sponsor":"Key Oncologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmaMar and Key Oncologics Have Signed an Exclusive Agreement to Commercialize Yondelis\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"SPAIN","productType":"Small molecule","productStatus":"Approved","date":"May 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"PharmaMar"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaMar has Filed Lurbinectedin for Temporary Marketing Authorisation with the Swiss Agency for Therapeutic Products","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"SPAIN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"PharmaMar"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Authorised Uses of Cancer Medicine Yondelis Unchanged Following Review of New Data","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"SPAIN","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"PharmaMar"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Onko Kocsel Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmaMar Signs a New Agreement with Onko to Commercialize Yondelis\u00ae in Turkey","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"SPAIN","productType":"Small molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"PharmaMar"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","amount":"$7.0 million","upfrontCash":"Undisclosed","newsHeadline":"PharmaMar signs an agreement with Jazz Pharmaceuticals for lurbinectedin in Canada","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"SPAIN","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"PharmaMar"},{"orgOrder":0,"company":"PharmaMar","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmaMar and STADA Sign Agreement to Commercialize Yondelis\u00ae (trabectedin) in the MENA Region","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"SPAIN","productType":"Small molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"PharmaMar"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Eczac\u0131ba\u015f\u0131 Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmaMar Signs a New Licensing and Commercialization Agreement With Eczacibasi for Lurbinectedin in Turkey","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"SPAIN","productType":"Small molecule","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"PharmaMar"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaMar Gets Approval Of Zepzelca For Treatment Of Metastatic Small Cell Lung Cancer In Switzerland","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"SPAIN","productType":"Small molecule","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"PharmaMar"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Adium Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pharmamar Signs a New Agreement with Adium Pharma S.A. to Commercialize Yondelis\u00ae in Latin America","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"SPAIN","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"PharmaMar"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pharmamar Receives US$10 Million Milestone Payment from Janssen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"SPAIN","productType":"Small molecule","productStatus":"Approved","date":"November 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"PharmaMar"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pharmamar Receives US$10 Million Milestone Payment from Janssen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"SPAIN","productType":"Small molecule","productStatus":"Approved","date":"December 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"PharmaMar"},{"orgOrder":0,"company":"Mabxience","sponsor":"Fresenius Kabi AG","pharmaFlowCategory":"D","amount":"$553.0 million","upfrontCash":"Undisclosed","newsHeadline":"Fresenius Kabi Buys a Majority Stake In mAbxience","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"SPAIN","productType":"Large molecule","productStatus":"Biosimilar","date":"March 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Mabxience"},{"orgOrder":0,"company":"Mabxience","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amneal Achieves Second U.S. Biosimilars Approval with ALYMSYS\u00ae (bevacizumab-maly)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"SPAIN","productType":"Large molecule","productStatus":"Biosimilar","date":"April 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Mabxience"},{"orgOrder":0,"company":"Mabxience","sponsor":"Zentiva","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zentiva Continues Its Expansion in Oncology with The Launch of Alymsys\u00ae (Bevacizumab) in 21 Countries Across Europe","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"SPAIN","productType":"Large molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Mabxience"},{"orgOrder":0,"company":"Mabxience","sponsor":"Fresenius Kabi AG","pharmaFlowCategory":"D","amount":"$553.0 million","upfrontCash":"Undisclosed","newsHeadline":"Fresenius Kabi Completes Majority Stake Acquisition Of mAbxience Holding S.L., Significantly Enhancing Presence in High-Growth Biopharmaceuticals Market","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"SPAIN","productType":"Large molecule","productStatus":"Biosimilar","date":"August 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Mabxience"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Through the agreement, Johnson will obtain the rights to commercialize Yondelis (trabectedin), a marine-derived anticancer drug utilized for the treatment of soft tissue sarcoma and relapsed ovarian cancer.

            Lead Product(s): Trabectedin

            Therapeutic Area: Oncology Product Name: Yondelis

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement November 06, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Zepzelca (lurbinectedin) inhibits oncogenic transcription in tumor-associated macrophages, downregulating the production of cytokines that are essential for the growth of the tumor.

            Lead Product(s): Lurbinectedin

            Therapeutic Area: Oncology Product Name: Zepzelca

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 08, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Through the agreement, Johnson will obtain the rights to commercialize Yondelis (trabectedin), a marine-derived anticancer drug utilized for the treatment of soft tissue sarcoma and relapsed ovarian cancer.

            Lead Product(s): Trabectedin

            Therapeutic Area: Oncology Product Name: Yondelis

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement December 12, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            mAbxience has developed and manufactured biological drugs, with commercialized biosimilar product Novex® (rituximab), through its in-house biosimilars programs and through its investment in mAbxience, Fresenius expects rapid growth in biopharmaceutical market.

            Lead Product(s): Rituximab

            Therapeutic Area: Oncology Product Name: Novex

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Fresenius Kabi AG

            Deal Size: $553.0 million Upfront Cash: Undisclosed

            Deal Type: Acquisition August 01, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            U.S.FDA has approved Company’s Biologics License Application for bevacizumab-maly, is a vascular endothelial growth factor inhibitor, a biosimilar referencing Avastin for first or second-line treatment metastatic colorectal cancer.

            Lead Product(s): Bevacizumab

            Therapeutic Area: Oncology Product Name: Alymsys

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Amneal Pharmaceuticals

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 13, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            mAbxience has developed and manufactured biological drugs, with commercialized biosimilar product Novex® (Rituximab), through its in-house biosimilars programs and through its investment in mAbxience Fresenius expects rapid growth in biopharmaceutical market.

            Lead Product(s): Rituximab,Cyclophosphamide,Doxorubicin Hydrochloride

            Therapeutic Area: Oncology Product Name: Novex

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Fresenius Kabi AG

            Deal Size: $553.0 million Upfront Cash: Undisclosed

            Deal Type: Acquisition March 31, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Eczacıbaşı will pursue the marketing authorization in Turkey and will have the right to commercialize the Zepzelca (Lurbinectedin), on an exclusive basis, upon approval. Lurbinectedin was granted accelerated approval by FDA for relapsed metastatic Small Cell Lung Cancer.

            Lead Product(s): Lurbinectedin

            Therapeutic Area: Oncology Product Name: Zepzelca

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Eczacıbaşı Group

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement December 22, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Alymsys (bevacizumab-maly) is a vascular endothelial growth factor inhibitor for the treatment of metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first or second-line treatment.

            Lead Product(s): Bevacizumab-maly,Fluorouracil,Calcium Folinate

            Therapeutic Area: Oncology Product Name: Alymsys

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Zentiva

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration April 09, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            PharmaMar has granted to STADA a license to market the Yondelis® (trabectedin) marine-derived cancer treatment in 15 Middle East-North Africa countries. Yondelis® is marketed in several MENA countries for the treatment of soft tissue sarcoma and relapsed ovarian cancer.

            Lead Product(s): Trabectedin

            Therapeutic Area: Oncology Product Name: Yondelis

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: STADA Arzneimittel

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement November 17, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            PharmaMar and Jazz Pharma have entered into an amended and restated license agreement of the US lurbinectedin license agreement signed in December 2019 for the purpose of granting Jazz an exclusive license for Zepzelca™ (lurbinectedin) in Canada.

            Lead Product(s): Lurbinectedin

            Therapeutic Area: Oncology Product Name: Zepzelca

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Jazz Pharmaceuticals

            Deal Size: $7.0 million Upfront Cash: Undisclosed

            Deal Type: Agreement October 15, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY